Turenne Capital
VC Fund
Paris, France
Turenne Capital is an independant private equity management company, with 4 offices in France : - Paris - Lyon - Marseilles - Lille (joint-venture). Since 1999, Turenne Capital has been taking significant minority or majority equity stakes alongside entrepreneurs who operate SMEs with revenues ranging from €5 million to € 100 million. Itinvests between €1 million and €10 million per transaction. Turenne Capital manages/advises more than € 500 million. 32 people, among which 21 investors work in the Group. ------------------------------------------------------------------------------ Turenne Capital est une Société de gestion indépendante spécialisée en capital investissement. Turenne Capital accompagne depuis 1999 des entrepreneurs dans leur développement et la transmission de leur société et est implantée à : - Paris - Lyon - Marseille - Lille (filiale) Les tickets d'investissement vont de '1 à 10 millions d'euros en minoritaire et majoritaire dans des PME de 5 à 100 M€ de Chiffre d'affaires. Le Groupe Turenne Capital compte 32 professionnels dont 21 investisseurs, et gère/conseille plus de 500 M€ confiés par des institutionnels et des particuliers.
- Total investments:
- 56
- Last investment:
- Lead investor:
- 25%
- Fund size:
- $35M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Turenne Capital invests in
Stages Turenne Capital invests in
Countries Turenne Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $2.8M–$33M
- Series B
- $6.6M–$30M
Investment Focus
Industry
- Software 13 (23%)
- Biotechnology 8 (14%)
- Health Care 7 (13%)
- Medical 6 (11%)
- Information Technology 5 (9%)
Stage
- Funding Round 16 (29%)
- Series A 13 (23%)
- Series B 8 (14%)
- Private Equity 8 (14%)
- Venture - Series Unknown 5 (9%)
Country
- France 47 (84%)
- Poland 1 (2%)
- Germany 1 (2%)
- United States 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alice Maurel
Marketing Assistant
|
Marketing Assistant | Total investments: 0 | Find email | |
Angélica Marlet
Assistant
|
Assistant | Total investments: 0 | Find email | |
Aurélie Viaux
Account Manager
|
Account Manager | Total investments: 0 | Find email | |
Béatrice Vernet
Secretary General
|
Secretary General | Total investments: 0 | Find email | |
Benoît Pastour
Deputy CEO
|
Deputy CEO | Total investments: 0 | Find email | |
| See all 20 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kainova Therapeutics
|
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $23.5M / Series B / Feb 09, 2026 | |
Germitec SAS
|
Germitec is a healthcare company that designs, Commercialize UV-C disinfection systems for hospital hygiene system. | $30.1M / Series B / Feb 12, 2025 | |
Coave Therapeutics
|
Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases. | $32.9M / Series A / Jan 09, 2025 | |
Sydev
|
Sydev is a publisher of management software and tariff databases for technical building trades in the construction industry. | $11.1M / Venture - Series Unknown / Sep 27, 2024 | |
Antabio
|
Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. Thecompany's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections.Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France. | $27M / Series B / Dec 12, 2023 | |
AlgoTherapeutix
|
AlgoTherapeutix is the operator of a biotechnology company designed to develop topical treatments for complex pain. | $21.5M / Series B / Mar 14, 2023 | |
Amolyt Pharma
|
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $138.6M / Series C / Jan 06, 2023 | |
Tradim
|
Tradim delivers commission, development and maintenance activities for the waste management hardware and integrated software. | $19.5M / Venture - Series Unknown / Oct 13, 2022 | |
|
Kainova Therapeutics
|
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $41.1M / Series A / May 10, 2022 | |
PathoQuest
|
PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $15.9M / Series B / Nov 09, 2021 | |
| See all 56 investments → | |||
Co-Investors
Bpifrance
7 deals together
Kurma Partners
5 deals together
Paca Investissement
5 deals together
Eurazeo
4 deals together
Omnes Capital
4 deals together
Panacea Venture
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Turenne Capital invest in?
Turenne Capital invests primarily in Software, Biotechnology and Health Care startups, most often at Funding Round and Series A stage. Most of the 56 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Turenne Capital's check size?
Turenne Capital typically joins rounds of $2.8M–$33M at Series A and $6.6M–$30M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Turenne Capital participates in.
How do I contact Turenne Capital?
Public channels for Turenne Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Turenne Capital?
The team at Turenne Capital includes Alice Maurel (Marketing Assistant), Angélica Marlet (Assistant) and Aurélie Viaux (Account Manager), among 20 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
